Effect of self-help cognitive behavioral therapy for insomnia combined with trazodone hydrochloride on elderly patients with depression and insomnia / 中国医师杂志

Objective:To observe the efficacy of self-help cognitive behavioral therapy for insomnia (CBTI), trazodone hydrochloride and their combination in the treatment of depression and insomnia comorbidity in the elderly.Methods:90 elderly patients with insomnia and depression admitted to the 901th Hospital of the Joint Logistic Support Force from October 2019 to October 2021 were selected as the study subjects. They were divided into trazodone group, CBTI group and trazodone combined with CBTI group(combination group), with 30 cases in each group. Trazodone group was treated with oral trazodone hydrochloride, CBTI group was treated with self-help CBTI, and the combination group was treated with oral trazodone hydrochloride combined with self-help CBTI. All three groups were treated for 4 weeks. The sleep latency, total sleep time and sleep efficiency of each group were compared at the time of admission and after 4 weeks of treatment. Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used for sleep assessment before and after treatment, and Self-Rating Depression Scale (SDS) was used for depression assessment.Results:Before treatment, there was no significant difference among the three groups in terms of sleep latency, total sleep time, sleep efficiency, PSQI, ESS and SDS (all P>0.05). After treatment, the sleep latency of the three groups was shorter than that before treatment, and the total sleep time was longer than that before treatment (all P<0.05). The sleep efficiency of the trazodone group and the combination group was higher than that before treatment, with statistically significant difference (both P<0.05). The indexes of the combined group were better than those of the trazodone group and the CBTI group (all P<0.05). The sleep latency of the trazodone group was shorter than that of the CBTI group, and the total sleep time was longer than that of the CBTI group (all P<0.05), with statistically significant difference (all P<0.05). After treatment, the PSQI, except for the SDS of CBTI group, the ESS and SDS of the three groups were lower than those before treatment (all P<0.05). The PSQI, ESS and SDS of the combined group were lower than those of the trazodone group and the CBTI group, and the ESS and SDS of the trazodone group were lower than those of the CBTI group, with statistically significant difference (all P<0.05). Conclusions:For the elderly patients with depression and insomnia, the combination of self-help CBTI and trazodone can not only improve insomnia but also relieve depression symptoms, and the effect is better than that of trazodone and self -help CBTI alone.

Alleviation of neuropathic pain by trazodone in rats

Abstract Neuropathic pain is generally characterised by an abnormal sensation (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to a stimulus that does not normally provoke pain (allodynia). The present study was designed to investigate the effect of trazodone (5mg/kg and 10mg/kg) on peripheral neuropathic pain induced by partial sciatic nerve ligation in rats. Mechanical hyperalgesia, cold allodynia and thermal hyperalgesia were assessed by performing the pinprick, acetone, and hot plate tests, respectively. Biochemically, lipid peroxidation level and total calcium levels were measured. However, trazodone administration (5 and 10 mg/ kg i.p.) for 21days significantly diminished partial sciatic nerve ligation-induced neuropathic pain along with areduction in oxidative stress and calcium levels. The results of the present study suggest that trazodone is effective in attenuating partial sciatic nerve ligation-inducedpainful neuropathic states, which may be attributed to decreased oxidative stress and calcium levels.

Determination of bis(2-chloroethyl)amine hydrochloride and 1-(3-chloropropyl)-4-(3-chlorophenyl)piperazine hydrochloride in trazodone hydrochloride by UPLC-MS/MS / 药学学报

An UPLC-MS/MS method was established for the quantification of the genotoxic impurities bis(2-chloroethyl)amine hydrochloride and 1-(3-chloropropyl)-4-(3-chlorophenyl)piperazine hydrochloride in trazodone hydrochloride. The chromatographic separation of the two genotoxic impurities was performed on Waters ACQUITY UPLC BEH C18 column (100 mm×2.1 mm, 1.7 μm) at 20 ℃. A mixture of 5 mmol·L-1 ammonium hydrogen carbonate aqueous solution and acetonitrile at a flow rate of 0.3 mL·min-1 in gradient elution mode was employed as mobile phase. The UPLC-MS/MS was equipped with electrospray ionization in positive ionization mode and adopted multiple reaction monitoring mode. We found that the calibration curves of the two genotoxic impurities were linear in the range of 0.1-10 ng·mL-1. The limit of detection was 0.10 ng·mL-1 for bis(2-chloroethyl)amine hydrochloride and the average recovery was 101.53% (RSD = 4.06%). The limit of detection was 0.01 ng·mL-1 for 1-(3-chloropropyl)-4-(3-chlorophenyl)piperazine hydrochloride and the average recovery was 97.95% (RSD = 1.27%). The sample solution was stable for 24 h. No bis(2-chloroethyl)amine hydrochloride was detected in the samples, and the content of 1-(3-chloropropyl)-4-(3-chlorophenyl)piperazine hydrochloride in the samples was within the limit. This research provides a method to improve the quality control standards of trazadone.

Randomized Controlled Trials of Efficacy and Safety of Trazodone Combined with Venlafaxine in the Treatment of Major Depressive Disorder / 中国药房

OBJECTIVE：To compare th e clinical efficacy and safety of trazodone combined with venlafaxine and venlafaxine in the treatment of major depressive disorder （MDD）. METHODS ：Totally 160 patients with MDD who were treated in our hospital from Sept. 2018 to Oct. 2020 were all enrolled and divided into control group （80 cases）and observation group （80 cases）according to random number table. Control group was treated with V enlafaxine hydrochloride sustained-release tablets 75 mg orally，once every morning. Observation group was additionally treated with Trazodone hydrochloride tablets 25 mg orally ，twice a day，on the basis of control group. The dosage was adjusted according to the efficacy and tolerance. Hamilton depression scale 24 （HAMD-24），Montgomery-Asperger depression scale （MADRS） and Pittsburgh sleep quality index （PSQI） were compared between 2 groups before and after treatment. Clinical efficacies were compared and the occurrence of ADR were recorded. RESULTS：A total of 12 patients were expelled ，and 148 patients were eventually included ，involving 73 cases in control group and 75 cases in observation group. Before treatment ，there was no significant differences in HAMD- 24，MADRS or PSQI scores between 2 group（P＞0.05）. After 1，3，5 and 8 weeks of treatment ，HAMD-24 and MADRS scores of 2 groups were significantly lower than before treatment ，and the observation group was significantly lower than the control group （P＜0.05）. PSQI scores of observation group were significantly lower than before treatment and control group during the same period （P＜0.05），while there was no significant difference in PSQI scores of control group before and after treatment （P＞0.05）. The total response rate of observation group （96.00％）was significantly higher than control group （86.30％）（P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS ：Trazodone combined with venlafaxine and venlafaxine alone both have good efficacy and similar safety in the treatment of MDD ， but clinical efficacy of trazodone combined with venlafaxine is better.

Effects of naltrexone hydrochloride combined with trazodone on preventing relapse in heroin addicts after detoxification / 中国基层医药

Objective:To investigate the effects of naltrexone hydrochloride combined with trazodone on preventing relapse in heroin addicts after detoxification.Methods:A total of 274 opioid heroin addicts who received treatment in Beijing Gaoxin Hospital between June 2016 and January 2019 were included in this study. After detoxification with methadone, all patients were randomly assigned to receive either naltrexone hydrochloride combined with trazodone (group 1, n = 60) or naltrexone hydrochloride alone (group 2, n = 60) for preventing relapse in heroin addicts. The effects on relapse prevention were determined in each group. Results:There were no significant differences in age distribution, sex composition, marital status, and drug use between groups 1 and 2 (all P > 0.05). After 6 months of treatment, the non-relapse rate was 86.7% (52/60) and 6.7% (4/60) in groups 1 and 2 respectively, in the case of unchanged personal life status. There was significant difference in non-relapse rate between groups 1 and 2 ( χ2 = 77.1, P < 0.001). Conclusion:Naltrexone hydrochloride combined with trazodone exhibits superior efficacy in preventing relapse in opioid heroin addicts after detoxification to naltrexone hydrochloride alone.

Trazodone-induced delirium: case report / Delirio inducido por trazodona: reporte de caso

ABSTRACT Trazodone is used as an antidepressant in doses between 150 and 600 mg. At lower doses, it is commonly used to treat insomnia. There are few case reports about confusional symptoms as an undesirable side effect of this drug. We report a case of a patient who presented with delirium after prescription of trazodone 100 mg. She required hospitalisation but, shortly after discontinuation of trazodone, the symptoms disappeared without antipsychotic medication. Seven months after the episode, the patient remains asymptomatic.

RESUMEN La trazodona se usa como antidepresivo en dosis de 150-600 mg. En dosis más bajas, se usa comúnmente para tratar el insomnio. Hay pocos reportes de caso sobre síntomas confusionales como un efecto secundario indeseable de este medicamento. Se presenta el caso de una paciente que acudió con delirio después de la prescripción de trazodona 100 mg. La paciente requirió hospitalización pero, poco después de la interrupción de la trazodona, los síntomas desaparecieron sin medicación antipsicótica. A los 7 meses del episodio, la paciente permanecía asintomática.

Preliminary study on the application value of trazodone combined with cognitive behavioral therapy in community detoxification management / 中国临床药理学与治疗学

AIM: To investigate the clinical application value of trazodone combined with cognitive behavioral therapy on heroin addicts during the period of community detoxification. METHODS: A total of 140 heroin addictive patients treated by community detoxification management were randomly divided into four groups, 35 patients were given trazodone combined with cognitive behavioral therapy (T+P group), 35 patients were given a single trazodone therapy (T group), 35 patients were given a single cognitive behavioral therapy (P group), and 35 patients were only given community detoxification management (S group), the course of the treatment lasted for 12 weeks. At the time-point of baseline and the weekends 4, 8 and 12 after treatment, four groups were scored by Hamilton anxiety rating scale (HAMA), Hamilton depression rating scale (HAMD), Pittsburgh sleep quality index scale (PSQI), psychological craving rating scale (PCS), Chinese perceived stress scale (CPSS), and urine morphine positive rate. The safety was evaluated with Treatment Emergent Side-effect Scale (TESS) and laboratory test. RESULTS: A total of 125 patients completed the 12 weeks of treatment. HAMA, HAMD and PSQI scores of T+P group and T group on weekends 4, 8 and 12 were significantly reduced when compared with baseline, respectively (P 0.05). CONCLUSION: Trazolone combined with cognitive behavior therapy can significantly improve the negative emotions, sleep quality and other related mental symptom of heroin addiction patients in the community detoxification period, and play a positive role in improving the quality of community detoxification management.

Avaliação do padrão de sono em insones usuários de benzodiazepínicos e análise da trazodona como medicação substitutiva / Evaluation of sleep pattern in insomnia in benzodiazepine users and analysis of trazodone as a substitute medication

RESUMO Objetivo Conhecer as modificações do padrão do sono em insones usuários crônicos de benzodiazepínicos (BZDs) após introdução da trazodona. Métodos Em um grupo de 11 pacientes, foi estabelecido esquema para retirada gradual do BZD com introdução progressiva da trazodona. Foram realizadas duas polissonografias, sendo a primeira com dose de BZD habitual do paciente e a segunda após supensão do BZD e com 150 mg de trazodona de liberação prolongada. Questionários de qualidade do sono (Pittsburgh), sonolência diurna (Epworth) e sintomas depressivos (Hamilton) e ansiosos (Beck) foram aplicados. Resultados Cinco indivíduos concluíram o estudo, tendo sido acompanhados por pelo menos seis semanas. Nesses pacientes, a trazodona aumentou significativamente a eficiência do sono e sono REM e diminuiu o tempo desperto após início do sono. Houve melhora da qualidade do sono, porém não houve alteração dos sintomas depressivos e ansiosos. Conclusão Trazodona de liberação prolongada demonstrou ser uma opção terapêutica para insones usuários crônicos de BZDs com retirada eficaz do ansiolítico. Houve melhora na qualidade do sono por questionário e polissonografia. Maior número de pacientes será necessário para determinar os benefícios da trazodona nesse tipo de intervenção.

ABSTRACT Objective To know the modifications of the sleep pattern in chronic benzodiazepine users after the introduction of trazodone. Methods In a group of 11 patients, a gradual withdrawal of benzodiazepine (BZD) was introduced with progressive introduction of trazodone. Two polysomnograms were performed, the first with BZD usual dose of the patient and the second after BZD suppression and with 150 mg of prolonged release trazodone. Sleep quality questionnaires (Pittsburgh), daytime sleepiness (Epworth) and depressive (Hamilton) and anxious (Beck) symptoms were applied. Results Five subjects completed the study and were followed up for at least six weeks. In these patients, trazodone significantly increased sleep efficiency and REM sleep and decreased wakefulness after sleep onset. There was an improvement in sleep quality, but there was no change in depressive and anxious symptoms. Conclusion Prolonged release trazodone has been shown to be a therapeutic option for chronic insomnia patients with benzodiazepines with effective withdrawal of the anxiolytic drug. There was improvement in sleep quality by questionnaire and polysomnography. More patients will be needed to determine the benefits of trazodone in this type of intervention.

Clinical study of sleep related rhythmic movement disorder / 中华神经科杂志

Objective To discuss the clinical and electrophysiological characteristics of sleep related rhythmic movement disorder ( SRMD).Methods We studied the clinical and electrophysiological characteristics of 3 patients diagnosed as SRMD in the Electroencephalography Monitoring Center of Xijing Hospital, Xi′an, China.The 3 patients accorded with diagnostic criteria of SRMD that international classification of sleep disorders-3 edition recommended and were followed up for more than 1 year.Results These 3 male patients were ranging from 6 to 27 years old.The onset age of the patient 1 was 13 years,and the others were 1 year old.The patient 2 became symptom-free at the age of 7.The patient 3 relieved at 2-year-old, but recurred at the age of 21. There was no epileptic seizure discharge in video-electroencephalography of the 3 patients, but synchronous electromyography changes during the attack were mistaken for slow wave.Video-polysomnography showed that numbers of awakenings and arousals index were high.Two patients were treated with clonazepam.One had an obvious curative effect, the other had marked efficacy until added trazodone.Conclusions SRMD can occur not only in infants, but also in adolescents and adults.Patients who have the problems of the sleep quality should be treated.Clonazepam can obviously relieve symptoms and improve sleep quality.Patients who do not have a good effect with clonazepam can try to add trazodone.Video-electroencephalography monitoring and interpreting it correctly are important to the diagnosis of paroxysmal disease.

Trazodona en el trastorno del comportamiento del sueño MOR / Trazodone in REM sleep behavior disorder

A un varón adulto mayor, con un cuadro clínico documentado de trastorno comportamental del sueño MOR, inicialmente se le ofreció tratamiento farmacológico con clonazepam, recomendado por la literatura, pero se obtuvo mala adherencia por intolerancia a los efectos secundarios y la persistencia sintomática. Por ese motivo, se propuso el tratamiento con trazodona y se logró control sintomático completo, sin efectos adversos reportados por el paciente. Es claro que la trazodona no tiene indicación conocida para este tipo de trastornos, pero se consideró en este caso por su perfil farmacológico y se obtuvo un resultado clínico satisfactorio. Se plantea la necesidad de realizar mayores estudios que permitan documentar de manera suficiente la acción, la eficacia y la utilidad de esta molécula en casos como el ilustrado.

This case concerns an elderly man with a REM sleep behavior disorder, who was initially offered a pharmacological treatment with clonazepam, recommended by other articles, but with poor adherence due to its adverse reactions and persistence of symptoms. He was then offered a treatment with Trazodone was offered, achieving a complete remission of symptoms, with no reported side effects. It is clear that Trazodone has no known indication for this type of disorder; nevertheless, it was considered in this case because of its pharmacological profile, obtaining satisfactory results. Further research is needed in order to document thoroughly the mechanisms of action, efficacy and utility of this molecule in cases such as the one presented.

Parkinsonismo induzido por trazodona durante o tratamento de hérnia discal lombar: relato de caso / Trazodone induced parkinsonism during lumbar disc herniation treatment: case report

A utilização de medicações psicoativas vem crescendo ao longo dos anos, sendo essencial o conhecimento de seus efeitos colaterais e interações medicamentosas. O desenvolvimento de distúrbios de movimento associados ao uso dessas substâncias é uma situação bastante desconfortável para o paciente, sendo essencial o diagnóstico adequado mediante forte suspeição. Relata-se o caso de um paciente que desenvolveu sintomas de parkinsonismo durante tratamento de hérnia discal lombar na vigência do uso de trazodona. É dada ênfase aos mecanismos de produção desse fenômeno e à sua condução clínica...

The use of psychoactive medications has been growing over years, being essential the knowledge of its side effects and interactions. The development of movement disturbances is a very uncomfortable situation for the patient, requiring a high suspicion for adequate diagnosis. A case of a patient who presented symptoms of Parkinsonism during use of Trazodone in the treatment of lumbar disc herniation is reported. Emphasis is given to the biological mechanisms of this phenomenon and its clinical conduction...

Prevalencia de interacciones potenciales evitables entre antidepresivos y otros medicamentos en pacientes colombianos / Prevalence of Avoidable Potential Interactions Between Antidepressants and Other Drugs in Colombian Patients

Objetivos: Determinar potenciales interacciones medicamentosas con antidepresivos y otros fármacos que pueden generar problemas relacionados con medicamentos mediante la búsqueda activa en bases de datos de pacientes afiliados al Sistema General de Seguridad Social en Salud. Métodos: Estudio descriptivo a partir de las bases de datos de dispensación de medicamentos de Audifarma S.A. a unos 4 millones de usuarios del pa ís; se hizo una revisión sistemática de potenciales interacciones de antidepresivos entre sí y con anticolinérgicos en los meses de octubre a noviembre y con tramadol durante todo el a ño 2010. Resultados: Se identificó un promedio mensual de 114.465 usuarios de antidepresivos. De estos, 5.776 (5,0 %) recibían dos antidepresivos simultáneamente y 178 (0,2 %), tres. La combinación más frecuente fue fluoxetina + trazodona (n = 3.235, el 56,9 % de los casos). A unos 1.127 (1,0 %) pacientes se les prescribió de manera simultánea un anticolinérgico. A 2.523 (2,1 %) usuarios se les dispensó al mismo tiempo tramadol, con lo que se elevaba el riesgo de aparición de síndrome serotoninérgico. Conclusiones: Las interacciones medicamentosas representan un riesgo potencial que muchas veces los médicos subestiman. La farmacovigilancia es una herramienta útil para optimizar recursos y prevenir resultados negativos relacionados con la medicación. Se recomienda considerar la búsqueda sistematizada para reforzar los programas de vigilancia de uso racional de medicamentos en el pa ís.

Objectives: To determine the possible drugs interactions with antidepressive agents in data bases of patients in the Health Insurance System of Colombia. Methods: From data bases of about 4 million users in Colombia, a systematic review of drugs dispensation statistics was made to identify drug interactions between antidepressive agents, cholinergic antagonists and tramadol in 2010. Results: We identified 114,465 monthly users of antidepressive agents. Of these, 5776 (5.0 %) received two, and 178 (0.2 %) received three antidepressive agents simultaneously. The most frequent combination was fluoxetine+trazodone (n =3235; 56.9 % of cases). About 1127 (1.0 %) patients were prescribed a cholinergic antagonist simultaneously; 2523 (2.1 %) users were dispensed tramadol at the same time, while raising the risk of serotonin syndrome. Conclusions: Drug interactions represent a potential risk that is often underestimated by physicians. Pharmacovigilance is a useful tool to optimize resources and prevent negative outcomes associated with medication. It is recommended that systematic search is made to enhance surveillance programs for the rational use of medicines in this country.

Comparison of Pharmacological Treatments for Burning Mouth Syndrome / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: Burning mouth syndrome (BMS) refers to a collection of symptoms of patients who complain about burning sensation of their mouths without any specific causes. Although this is not a rare disease, the etiology and effective treatment are not well established. We tried to compare the efficacy and side effects of the agents that are reported to be relatively effective to BMS. SUBJECTS AND METHOD: Fifty-one patients who were diagnosed as BMS were chosen as candidates. Trazodone, Paroxetine, Clonazepam, and Gabapentin, which were known to be effective medicines for BMS in previous research were prescribed randomly. We prescribed medication for two weeks and evaluated patients for the effect and side effects at the end of the treatment. The medication was prescribed for 2 more weeks and the patients were evaluated again. RESULTS: Three of 11 (27.3%) patients were prescribed Trazodone, 8 of 12 (66.7%) Paroxetine, 8 of 14 (57.1%) Clonazepam and 12 of 14 (85.7%) Gabapentin. Q showed improvements after 4 weeks of medication. The differential effectiveness among the medications was not significant, except for the inferiority of Trazodone. Five of 11 (45.5%) patients who had been prescribed Trazodone, 2 of 12 (16.7%) who had been prescribed Paroxetine, 2 of 14 (14.3%) who had been prescribed Clonazepam, 2 of 14 (14.3%) who had been prescribed Gabapentin complained of side effects during 4 weeks of medication. CONCLUSION: We can expect high success rates of treatment for burning mouth syndrome with Paroxetine, Clonazepam and Gabapentin. A further study for long term outcomes and side effects in large groups is warranted.

A clinical study of trazodone replacement treatment on benzodiazepine drugs dependence in senile patient / 中华行为医学与脑科学杂志

Objective To explore the efficacy of trazodone replacement treatment on benzodiazepine drugs dependence and effect of cognitive function on senile patients.Methods 51 senile patients with benzodiazepine drugs dependence were assigned with dosage tacho-decrement and replaced by trazodone.The patients were discontinuanced taking benzodiazepine in 14 days and taken at a draught of trazodone before retiring about 6 months.Clinical effect and side effects were assessed with the Pittsburgh sleep quality index (PSQJ) and treatment emergent symptom scale(TESS) before and after treatment.Cognitive function was evaluated with Wechsler intelligence scale for adult-Chinese revised (WAIS-RC) and Wechsler mermory scale for adult-Chinese revised ( WMS-RC ) once before and after treatment.Results The scores total PSQJ( ( 13.17 ± 3.70),( 11.05 ± 3.48 ) ),the sleep quality( (2.36 ± 0.33 ),( 1.91 ± 0.29 ) ),daily function disorder,sleep disorder were significantly lower than before treatment while the other factor scores were not significantly changed.Trazodone wes effective without severe side effects and dependence.The study group showed significantly lower scores in learning,calculation,the signs of figure,wood puzzles,long-term memory,short-term memory,immediate memory,memory quotient in the assessment of cognitive function than after treatmemt (P ＜ 0.05 ).Conclusion Trazodone is an ideal medicine to senile insomnia.

Patrones de prescripción de antidepresivos en pacientes afiliados al sistema general de seguridad social en salud de Colombia / Antidepressant prescription patterns in patients affiliated with the general social security health system of Colombia

OBJETIVO: Determinar los patrones de prescripción de medicamentos antidepresivos en un grupo de afiliados al Sistema General de Seguridad Social en Salud de Colombia. MÉTODOS: Estudio descriptivo observacional con 9 881 pacientes medicados con antidepresivos, de ambos sexos, mayores de 5 a±os, con tratamiento continuo de agosto a octubre de 2009 y residentes en 56 ciudades colombianas. Se dise±ó una base de datos sobre consumo de medicamentos, obtenidos por la empresa que distribuye los medicamentos a los pacientes. RESULTADOS: Edad promedio de 59,1 ± 16,1 a±os; 73,7 por ciento de los participantes fueron mujeres. Del total de pacientes, 83,3 por ciento recibían monoterapia y 16,7 por ciento dos o mßs antidepresivos. El orden de prescripción de los medicamentos fue: inhibidores selectivos de la recaptación de serotonina 47,0 por ciento, atípicos 37,8 por ciento, tricíclicos 31,8 por ciento, inhibidores selectivos de la recaptación de serotonina y norepinefrina 1,8 por ciento e inhibidores selectivos de la recaptación de norepinefrina 0,03 por ciento. Las combinaciones mßs empleadas fueron fluoxetina + trazodona (n = 1 029), amitriptilina + fluoxetina (n= 265), amitriptilina + trazodona (n = 122), fluoxetina + imipramina (n = 106) e imipramina + trazodona (n = 71). Las comedicaciones mßs prescritas fueron antihipertensivos (52,3 por ciento), hormona tiroidea (23,3 por ciento), antiinflamatorios (19,6 por ciento), antiepilépticos (15,4 por ciento), antidiabéticos (13,8 por ciento), ansiolíticos e hipnóticos (12,4 por ciento), antipsicóticos (7,4 por ciento), antiparkinsonianos (4,3 por ciento) y antineoplßsicos (2,2 por ciento). CONCLUSIONES: Predominan hßbitos de prescripción de medicamentos de alto valor terapéutico, principalmente en monoterapia antidepresiva. La mayoría de los antidepresivos se emplean en dosis menores que las recomendadas. Se plantea la necesidad de dise±ar estrategias educativas para corregir algunos hßbitos de prescripción...

OBJECTIVE: Determine patterns of antidepressive drug prescription in a group of patients affiliated with the General Social Security Health System in Colombia. METHODS: Observational descriptive study of 9 881 patients, of both sexes and older than 5 years of age, medicated with antidepressants and continuously treated from August to October 2009. The patients include residents from 56 Colombian cities. A database was designed based on the consumption of medicines obtained from the company that distributes them to the patients. RESULTS: The average age was 59.1 ± 16.1 years; 73.7 percent of the participants were women. Of the total number of patients, 83.3 percent were treated with monotherapy and 16.7 percent with two or more antidepressants. The order of the prescription of the medicines was: selective serotonin reuptake inhibitors, 47.0 percent; atypical, 37.8 percent; tricyclical, 31.8 percent; selective serotonin reuptake inhibitors and norepinephrine, 1.8 percent; and selective norepinephrine reuptake inhibitors, 0.03 percent. The combinations most used were fluoxetine + trazodone (n = 1 029); amitriptyline + fluoxetine (n = 265); amitriptyline + trazodone (n = 122); fluoxetine + imipramine (n = 106); and imipramine + trazodone (n = 71). The most prescribed co-medications were anti-hypertensives (52.3 percent); thyroid hormones (23.3 percent); anti-inflammatories (19.6 percent); anti-epileptics (15.4 percent); anti-diabetics (13.8 percent); anti-anxiety and hypnotics (12.4 percent); antipsychotics (7.4 percent); anti-Parkinsons (4.3 percent); and anti-neoplastics (2.2 percent). CONCLUSIONS: The practice of prescribing medicines with a high therapeutic value predominates, mainly for antidepressive monotherapy. Most of the antidepressants are prescribed at dosages lower than those recommended. There is a need to design educational strategies to correct some prescription practices and to conduct research.

Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study / Trazodona para o tratamento de distúrbios do sono em demência: um estudo aberto, observacional e de revisão

Sleep disorders (SD) in patients with dementia are very common in clinical practice. The use of antidepressants with hypnotic actions, such as trazodone, plays an important role in these cases. The aim of this study is to present a profile of the use of trazodone in demented patients with SD, as well as a review of trazodone hydrochloride in SD. We evaluated 178 elderly patients with Alzheimer's disease and other dementias, clinically presenting SD and treated with hypnosedative medications. In the one-year period comprising the study, 68 (38.2 percent) of the 178 had sleep disorders. Most patients (114; 64 percent) had a diagnosis of Alzheimer's disease. Approximately 85 percent of patients with SD used hypnosedative drugs. Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65.7 percent. Trazodone has been shown to be a good option for treatment of the elderly with dementia and associated SD.

Distúrbios do sono (DS) em pacientes com demência são muito comuns na prática clínica. O uso de antidepressivos com ação hipnótica, como a trazodona, tem um papel importante nesses casos. O objetivo desse estudo é apresentar um perfil do uso da trazodona em pacientes com demência e com DS, bem como revisar o cloridrato de trazodona no DS. Nós avaliamos 178 idosos com doença de Alzheimer (DA) e outras demências, clinicamente apresentando DS e que foram tratados com medicações hipnossedativas. No período de um ano de estudo, 68 (38,2 por cento) tiveram DS. A maioria (114; 64 por cento) tinham diagnóstico de DA. Aproximadamente 85 por cento usaram fármacos hipnossedativos. A trazodona foi a mais utilizada (N=35), com evidência de melhora de 65,7 por cento. A trazodona mostrou-se ser uma boa opção no tratamento de idosos com demência e DS associado.

Observation on the efficacy and safety of physical and psychological symptoms in the inpatients with alcohol dependence after Trazodone treatment / 中华行为医学与脑科学杂志

Objective To explore the efficacy and safety of anxiety, depression, insomnia and other psychological and physical symptoms after trazodone treated in patients with alcohol dependence. Methods 100 patients whose met the inclusion and exclusion criteria were divided into trazodone group and the placebo group with a randomized, double-blind, placebo-controlled method. Each of the patients was oral trazodone, or placebo 3 times a day, each time a course of treatment was 8 weeks. Hamilton Anxiety Scale ( HAM A) , Hamilton Depression Rating Scale(HAMD) , Pittsburgh Sleep Quality Index(PSQI) , side effects scale (TESS) score and the necessary examinations were used to assess. Survey the re-drink situation after 1 year. Results 81 patients completed treatment, 19 patients were discharged or lost due to early treatment failure loss. In Trazodone group (41 cases) , the HAMA, HAMD and PSQI score before treatment and after treatment, total scores decreased gradually after 2 weeks of the three score and comfort dose group (40 cases) were the difference was statistically significant (P 0. 05 ). Conclusion Improve trazodone treat alcohol dependence withdrawal anxiety, depression and insomnia effectively. Found no adverse drug reactions and the safety is high. Reduce the recovery drink.

Possible role of NO modulators in protective effect of trazodone and citalopram (antidepressants) in acute immobilization stress in mice.

Stress is an aversive stimulus which disturbs physiological homeostasis and is reflected on a variety of biological systems. The present study was designed to investigate the nitric oxide mechanism in neuroprotective effect of trazodone and citalopram against acute immobilization-induced behavioral and biochemical alteration in mice. Mice were immobilized for a 6 h. Acute immobilization stress caused anxiety, hyperalgesia, impaired locomotor activity and oxidative damage. Pre-treatment with trazodone and citalopram significantly reversed immobilized stress-induced behavioral and biochemical alterations. L-arginine, pretreatment with trazodone or citalopram significantly reversed their protective effects. However, L-NAME or methylene blue pretreatment with trazodone or citalopram significantly potentiated their protective effects alone. Results suggest the involvement of nitric oxide pathways in the protective effect of trazodone and citalopram against immobilization stress induced behavioral and biochemical alterations.

Effect of Levofloxacin combined with tamsulosin and trazodone medication in treatment of chronic bacterial(Ⅲ)prostatitis(a 118cases)analycis / 中国基层医药

Objective To elxplore the effect of combined with tamsulosin and trazodone medication in treatment of chronic bacterial prostatitis(CAP,type Ⅲ). Methods118 cases of CAP were treated with oral levofioxacin + tamsulosin + trazodone for 4 ～ 12 weeks.Statistical analysis was conducted for total scores(including pain score,urinary symptom score and life quality score)according to NIH-CPSI. ResultsThe symptoms were improved in most cases.Before and after treatment,the total scores were of all cases(26.81 ± 3.69)VS(13.41 ± 5.31),the pain score was(12.81 ±2.52)VS(8.91 ±3.51),the urinary symptom score was(5.76 ± 1.89)VS(2.79 ± 1.38),and the life quality score was(9.12 ±3.21)VS(4.28 ±2.46).There was statistically significant difference between them (all P＜0.01). ConclusionLevofloxacin combined with tamsulosin and trazodone medication in treatment of CAP could produce obvious effects.

The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease / Uso de um antagonista 5-HT2a/c na depressão e na função motora de pacientes com doença de Parkinson

OBJECTIVE: To test the ability of a 5HT2a/c (trazodone) antagonist, to improve depression and motor function in Parkinson' disease (PD). METHOD: Twenty PD patients with and without depression were randomly assigned to receive trazodone (group 1) or not (group 2). They were evaluated through UPDRS and Hamilton Depression Rating Scale (HAM-D). RESULTS: For the UPDRS the mean score of group 2 was 33.1 ± 19.7 and 37.1 ± 18.0 at the end. For the group 1, the corresponding scores were 31.4 ± 11.3 and 25.9 ± 13.7. The variations in the Mann-Whitney test were 0.734 at the initial moment and 0.208 at the final moment. The variation in the comparison of the initial moment with the final moment was 0.005 providing statistical significance. For the HAM-D, the mean score went up 4 points in group 2, contrary to a 5.5 points decrease in group 1. CONCLUSION: Data analysis shows that this agent significantly improves depression, but the motor function improved only in the depressed patients. Because of the known anti-dopaminergic property of the 5-HT2c receptors, a possible approach for depression in PD could be the use of 5-HT2c antagonists, similarly to the use of atypical neuroleptics in case of psychotic symptoms.

OBJETIVO: Avaliar a eficácia de um antagonista 5-HT2a/c (trazodona) na depressão e na função motora de pacientes com doença de Parkinson (DP). MÉTODO: Vinte pacientes com DP com e sem depressão foram randomizados e divididos em 2 grupos com e sem a trazodona (grupos 1 e 2). Foram avaliados pela escala UPDRS e a de depressão de Hamilton (EDH). RESULTADOS: A média inicial do grupo 2 na UPDRS foi 33,1 ± 19,7 no momento inicial e 37,1 ± 18,0 no final. Para o grupo 1 as médias correspondentes foram 31,4 ± 11,3 e 25,9 ± 13,7. As variações no teste de Mann-Whitney foram 0,734 no momento inicial e de 0,208 no final. A variação na comparação entre o momento inicial e o final foi 0,005, caracterizando significância estatística. Para a EDH a média subiu 4 pontos no grupo 2, e desceu 5,5 pontos no grupo 1. CONCLUSÃO: A análise estatística revelou melhora da depressão, porém o benefício na função motora foi obtido apenas entre os deprimidos. Do mesmo modo que os neurolépticos atípicos atuam nos sintomas psicóticos, a ação secundária dopaminérgica do antagonista 5-HT2c pode ser útil no tratamento da depressão na DP.